METHOD FOR ANTICOAGULANT THERAPY AND PREVENTION OF THROMBOTIC COMPLICATIONS IN PATIENTS WITH SEVERE BRAIN DAMAGE IN A CHRONIC CRITICAL CONDITION Russian patent published in 2021 - IPC A61K31/4439 A61K31/5377 A61P7/02 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely neurology, and can be used in the treatment and prevention of thrombotic complications in patients with severe brain damage in a chronic critical condition. The method includes the administration of oral anticoagulants rivaroxaban or dabigatran in the absence of contraindications in the form of gastrointestinal dysfunction, severe hepatic or renal insufficiency, severe thrombocytopenia less than 100x10⁹/l: Rivaroxaban orally at a therapeutic dose of 15 mg 2 t/day for 21 days, followed by a dose reduction to prophylactic 20 mg/day or Dabigatran etexilate orally at a therapeutic dose of 110-150 mg 2 t/day up to 6 months, followed by a reduction in the dose to the preventive 110-150 mg/day. With thrombocytopenia 100-200×10⁹/l, a prophylactic dose of drugs is prescribed: Rivaroxaban 10-20 mg/day or Dabigatran etexilate 110-150 mg/day until thrombocytopenia is eliminated. The introduction of anticoagulants is canceled 48 hours before the planned surgical intervention and no later than 12 hours before the start of an urgent operation and is prescribed again 12 hours after the completion of surgical treatment.

EFFECT: use of the invention makes it possible to reduce the risk of complications, reduce the side effects of anticoagulant therapy, and shorten the duration of treatment.

1 cl, 6 ex